QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=0F62AD57107DF9D49BFCDEB9401817EC;jsessionid=2F2A3216137F3E590CE727FF0B4C92D2;jsessionid=83FB169AC20A50822260F9974618FB02;jsessionid=00A77FF45DE8089BE4B95E95CDD70E56;jsessionid=8F02459A0647DEC8EB5B304DFEAAA0DC;jsessionid=199B66188E44D3394CF487E03A90B0FB;jsessionid=FD45B962B21D6C5BA1A30036520D01AE;jsessionid=B0D8A49A84A16FEFDB21A417CED38D51;jsessionid=E566123C92729E9F4C83D6B029A951CF (gene)

1. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
2. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…
3. The RNA-binding protein and stress granule component ATAXIN-2 is expressed in mouse and human tissue…
4. Ataxin-2 gene: a powerful modulator of neurological disorders.
5. Antagonistic roles for Ataxin-2 structured and disordered domains in RNP condensation.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=0F62AD57107DF9D49BFCDEB9401817EC;jsessionid=2F2A3216137F3E590CE727FF0B4C92D2;jsessionid=83FB169AC20A50822260F9974618FB02;jsessionid=00A77FF45DE8089BE4B95E95CDD70E56;jsessionid=8F02459A0647DEC8EB5B304DFEAAA0DC;jsessionid=199B66188E44D3394CF487E03A90B0FB;jsessionid=FD45B962B21D6C5BA1A30036520D01AE;jsessionid=B0D8A49A84A16FEFDB21A417CED38D51;jsessionid=E566123C92729E9F4C83D6B029A951CF